Qualigen Therapeutics Inc
NASDAQ:QLGN
Intrinsic Value
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of QLGN.
Qualigen Therapeutics Inc's market capitalization is 1.6m USD.
QLGN stock price is 0.2974 USD.
QLGN.
QLGN. Open DCF Valuation
QLGN. Open Relative Valuation
QLGN.
QLGN has a very low three-year average ROE (Return on Equity): 4%. The company is not efficient at transforming stockholders' equity into net income.
QLGN's ROE (Return on Equity) has significantly decreased in the last 3 years from -286% to -522%, and is approaching profitability.
QLGN's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 158% to -213%, and is approaching profitability.
QLGN has positive Net Debt. This means that the company has more debt (1m USD) than cash and short-term investments (402k USD).
QLGN has negative Operating Income for the last twelve months.
QLGN has negative Net Income for the last twelve months.
QLGN's ROE (Return on Equity) for the past 12 months is negative and is equal to -522%.
QLGN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -213%.
QLGN's long-term liabilties (4m USD) exceed its long-term assets (2m USD).
QLGN has negative Free Cash Flow for the last twelve months.
QLGN's short-term liabilties (4m USD) exceed its short-term assets (1m USD).
QLGN has negative three-year average ROIC (Return on Invested Capital): -389%. The company is not efficient at using invested capital to generate operating income.
QLGN's D/E (Debt to Equity) is very low and is equal to -0.62.
QLGN's Altman Z-Score is very low and is equal to -99.57.
Fundamental Analysis
Qualigen Therapeutics Inc
Balance Sheet Decomposition
Qualigen Therapeutics Inc
| Current Assets | 1.2m |
| Cash & Short-Term Investments | 401.8k |
| Other Current Assets | 765k |
| Non-Current Assets | 866.5k |
| Other Non-Current Assets | 866.5k |
| Current Liabilities | 4.1m |
| Accounts Payable | 2.2m |
| Accrued Liabilities | 527k |
| Short-Term Debt | 1.3m |
| Other Current Liabilities | 87.6k |
Earnings Waterfall
Qualigen Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-11.3m
USD
|
|
Operating Income
|
-11.3m
USD
|
|
Other Expenses
|
-2.1m
USD
|
|
Net Income
|
-13.4m
USD
|
Free Cash Flow Analysis
Qualigen Therapeutics Inc
What is Free Cash Flow?
QLGN Profitability Score
Profitability Due Diligence
Qualigen Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Qualigen Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
QLGN Solvency Score
Solvency Due Diligence
Qualigen Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Qualigen Therapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QLGN Price Targets Summary
Qualigen Therapeutics Inc
Ownership
QLGN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
QLGN Price
Qualigen Therapeutics Inc
| Average Annual Return | -66.97% |
| Standard Deviation of Annual Returns | 21.37% |
| Max Drawdown | -100% |
| Market Capitalization | 1.6m USD |
| Shares Outstanding | 5 181 060 |
| Percentage of Shares Shorted | 1.27% |
Company Profile
Qualigen Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Los Angeles, California and currently employs 39 full-time employees. The company went IPO on 2015-06-24. The firm's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.
You don't have any saved screeners yet
